How we work to restore a sound
and balanced reality for patients
Over the last decade, we have established the leading drug development company in neurotology. With our first product in-market in the United States, the most clinical trials conducted, and the broadest product pipeline in the field, Otonomy will continue to advance the development of new drug treatments for patients with hearing and balance disorders.
In order to treat neurotological conditions, we need to understand the underlying biology, identify a potential treatment and deliver the drug to where it's needed. Our scientists are experts in the microscopic realm of cochlear hair cells and spiral ganglion neurons—true miracles of biology with their specialized structures and functions.
We are product developers. Sure, our scientists love making new discoveries about the biology of the inner ear, but at the end of the day it serves as the means to an end: identifying drug treatments—whether a small molecule, protein or even gene therapy—that can make a difference for patients.
Otonomy was the first company to realize the importance of local drug delivery for neurotology conditions, much in the same way that intravitreal treatments revolutionized the treatment of retinal disorders. We are experts in designing and developing formulations that provide sustained drug exposure from a single intratympanic injection. We have established a broad patent estate to protect our inventions.